Alexey Vinogradov
Director/Board Member at XENETIC BIOSCIENCES, INC.
Net worth: 70 532 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alexey Shafranov | M | 45 | 19 years | |
| Carmine Stengone | M | 48 |
Avelas Biosciences, Inc.
 Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | 12 years |
| Petr Vladimirovich Kruglyakov | M | 46 | 11 years | |
| Dmitriy Genkin | M | 56 | 19 years | |
| Jay Lichter | M | 62 |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
| Grigory Borisenko | M | 55 | 5 years | |
| James Callaway | M | 68 | 7 years | |
| Artem Vladimirovich Orlov | M | 48 | 11 years | |
| Roman Sergeevich Knyazev | M | 44 | 11 years | |
| Sergey Avtushenko | M | 56 | 17 years | |
| James Parslow | M | 59 | 7 years | |
| Roger Kornberg | M | 77 | 8 years | |
| Dmitry Yuryevich Kolosov | M | 44 | 11 years | |
| Adam Logal | M | 46 | 7 years | |
| Firdaus Jal Dastoor | M | 72 | 10 years | |
| Timothy Scott | M | - |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
| Robin Stevenson | M | - |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | 3 years |
| Efim Prilezhaev | M | - | 1 years | |
| Nina Podkolzina | F | 50 | 1 years | |
| Stefan Heller | M | 58 |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
| Robin Stevens | M | 71 |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
| Moshe Mizrahy | M | 71 | - | |
| Sergey Kimovich Bezhanov | M | 65 | - | |
| Susan P. Stimson | F | 51 |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | 5 years |
| Vladimir Olegovich Kutyrov | M | 57 | - | |
| Yuliya Yurievna Yakovleva | F | 53 | - | |
| Pavel Rodyukov | M | - | 1 years | |
| Steve Gorelik | M | 45 | 17 years | |
| Roza Vasilyevna Mikhaylova | F | - | - | |
| Dmitriy Nikolayevich Poznyak | M | - | - | |
| Indrek Kasela | M | 52 | 17 years | |
| Alexandra Vladimirovna Tuchkova | F | - | - | |
| Olga Yuryevna Shpichko | M | 49 | 11 years | |
| Jesus E. Gonzalez | M | - |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
| Ivan Ozhgikhin | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Eisenberg | M | 58 | 8 years | |
| David Gryska | M | 68 | 2 years | |
| Brian Underdown | M | 83 | 17 years | |
| Jean Lamarre | M | 70 | 2 years | |
| Curtis Lockshin | M | 64 | 10 years | |
| Philippe van Holle | M | 69 | 2 years | |
| John D. Menditto | M | - | 2 years | |
| Lee F. Allen | M | 72 | 1 years | |
| Frederick M. Miesowicz | M | 75 | 13 years | |
| Olga Bioprocess Golub | F | - |
Bioprocess Capital Partners Ltd.
 Bioprocess Capital Partners Ltd. Investment ManagersFinance Bioprocess Capital Partners Ltd (BCP) is a venture capital firm founded in 2006. The firm is headquartered in Moscow, Russia. | 1 years |
| Igor Krol | M | 51 | - | |
| Joan C. Winterbottom | F | 67 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 28 | 59.57% |
| Russia | 21 | 44.68% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alexey Vinogradov
- Personal Network
